Rainbow will offer Color's hereditary cancer and heart health genetic risk assessment tests to patients in Hong Kong.
Pro-Lab will shepherd Medicortex's kit through the regulatory processes in Canada and the UK, as well as clinically validate it. It will have exclusive rights to sell the kit in the two nations.
Sphingotec's proenkephalin and adrenomedullin biomarkers and Nexus Dx's Nexus IB 10 point-of-care testing platform will be merged under jointly owned holding company Polaris MediNet.
The partners will combine Chembio's DPP technology and biomarkers developed at Mass General for diagnostic tests for typhoid and febrile illness.
FIND is granting an award to Altona Dx, Cepheid, and the Bernhard Nocht Institute to develop an assay for Lassa virus. It also signed an MOU with the UK government to combat antimicrobial resistance.
Roche is developing an immunohistochemnistry assay for Pierre Fabre's oncology drug candidate, an antibody drug conjugate targeting insulin-like growth factor 1 receptor.
Under a collaboration with GeneDx, Boston Children's has rapidly sequenced the exomes of 20 NICU babies and have arrived at a likely diagnosis in around 85 percent.
The companies have signed a deal under which each will make its tests available to the other's customer base.
The partners will develop an amyloid β 42/40 ratio assay to identify patients who may benefit from treatment with Janssen's drug called atabecestat.
The clinical analysis lab will use more than 50 Atellica clinical chemistry and immunoassay analyzers among 100 analyzers produced by Siemens.